awmsg logo



histamine dihydrochloride (Ceplene®)


Reference No. 346

Publication date:
02/11/2011


Appraisal information

histamine dihydrochloride (Ceplene®) 0.5 mg/0.5ml solution for injection


Company: Meda Pharmaceuticals Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 10/03/2011
AWMSG meeting date: 13/04/2011
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 0411
Ratification by Welsh Government: 02/11/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Histamine dihydrochloride (Ceplene®) is not recommended for use within NHS Wales for maintenance therapy for adult patients with acute myeloid leukaemia in accordance with its licensed indication. The case for clinical effectiveness and cost effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download